Blog
RSS FeedPosted by Michael Wonder on 31 Oct 2018
Schedule of Pharmaceutical Benefits - 1 November 2018 update
1 November 2018 - The November 2018 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 31 Oct 2018
NICE to retire guidance app
31 October 2018 - Following improved access and optimisation of the website, the NICE guidance app will no longer be available ...
Posted by Michael Wonder on 31 Oct 2018
More insights from the first tranche of Public Summary Documents from the July 2018 PBAC meeting
31 October 2018 - A thorough examination of the Public Summary Documents from the July 2018 PBAC meeting has identified ...
Posted by Michael Wonder on 31 Oct 2018
New Zealand Pharmaceutical Schedule - 1 November 2018 update
31 October 2018 - The November 2018 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 30 Oct 2018
Jeanette Kusel is appointed as Director for NICE Scientific Advice
30 October 2018 - NICE has announced the appointment of Jeanette Kusel as Director for NICE Scientific Advice. ...
Posted by Michael Wonder on 30 Oct 2018
Analysis of base-case ICERs accepted by the PBAC (July 2018)
30 October 2018 - There appear to be one or two examples where the PBAC accepted a higher than usual ...
Posted by Michael Wonder on 30 Oct 2018
Proposal to change how discarded medicines are reimbursed
30 October 2018 - PHARMAC is seeking feedback on a proposal to change how the agency reimburses discarded medicines in ...
Posted by Michael Wonder on 29 Oct 2018
Mavenclad (cladribine tablets) receives positive CADTH Canadian Drug Expert Committee recommendation
29 October 2018 - Funding recommendation marks an important step to provide access to this innovative new oral treatment for Canadians ...
Posted by Michael Wonder on 29 Oct 2018
NICE turns down hyperkalaemia therapies
29 October 2018 - Preliminary guidelines released by the NICE do not recommend NHS funding for hyperkalaemia treatments Lokelma and ...
Posted by Michael Wonder on 29 Oct 2018
Is 'lowest cost alternative' rapidly becoming the most common main comparator accepted by the PBAC?
29 October 2018 - Further analysis of the first round of Public Summary Documents from the July 2018 PBAC meeting ...
Posted by Michael Wonder on 28 Oct 2018
Is the PBAC's stance on the choice of the main comparator changing?
29 October 2018 - Analysis of the first round of Public Summary Documents from the July 2018 PBAC meeting reveals ...
Posted by Michael Wonder on 28 Oct 2018
Update on proposal to move to one funded brand of lamotrigine (Logem)
26 October 2018 - PHARMAC would like to thank everyone who provided feedback on a proposal to move to one ...
Posted by Michael Wonder on 28 Oct 2018
Calls for PHARMAC review after funds made available to offset wage settlements
24 October 2018 - A request that the government's drug-buying agency be reviewed has opposition support with claims money is ...
Posted by Michael Wonder on 28 Oct 2018
PBAC Public Summary Documents - July 2018 meeting
26 October 2018 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the July 2018 PBAC ...
Posted by Michael Wonder on 28 Oct 2018
Potent drugs to treat lung cancer and high cholesterol added to PBS
28 October 2018 - Australians with advanced lung cancer and a genetic high-cholesterol condition will have cheaper access to potent ...